Stellarex Drug Coated Angioplasty Balloons – Vascupedia
Drug-Coated Balloon for De Novo Coronary Artery Disease: JACC State-of-the-Art Review | Journal of the American College of Cardiology
Safety of Paclitaxel-Coated Balloon Angioplasty for Femoropopliteal Peripheral Artery Disease - ScienceDirect
Stellarex Drug-coated 0.035" angioplasty balloon | Philips
Drug Coated Balloon | VuMedi
Drug-Eluting Stent Versus Drug-Coated Balloon Revascularization in Patients With Femoropopliteal Arterial Disease - ScienceDirect
Drug-Coated Balloons Market - Global Outlook and Forecast 2020-2025
Stellarex Drug-coated 0.035" angioplasty balloon | Philips
Drug Eluting Balloon Market Size, Growth, Trends and Forecast to 2028 | Medtronic, Becton, Boston Scientific Corporation | Medgadget
Philips Introduces New 200mm and 150mm Stellarex 0.035-inch Low-dose Drug-coated Balloons | DAIC
Drug-Eluting Balloon Market Size & Share | Report 2022, 2027
Stellarex Drug-coated 0.035" angioplasty balloon | Philips
Latest data from Philips reinforces the safety profile of Stellarex low-dose DCB - Vascular News
Recent FDA Approvals for Drug-eluting Balloons - Drug-eluting Balloons
Drug Eluting Balloon Market Size & Share Analysis - Industry Research Report - Growth Trends
Stellarex Drug-coated 0.035" angioplasty balloon | Philips
Signal of Late Deaths With Paclitaxel-Coated DCBs and Stents for PAD Warrants Urgent Review, Authors Say | tctmd.com
Philips Shares Three-Year Results for Stellarex .035 Drug-Coated Balloon | DAIC
Four-year results from patient-level meta-analysis confirm safety profile of Philips Stellarex 0.035 low-dose drug-coated balloon - Interventional News
Stellarex Drug-coated 0.035" angioplasty balloon | Philips
